Rivaroxaban in the contemporary treatment of acute coronary syndromes

Bibliography

• Alpert JS, Thygesen K, Antman E, Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36(3):959-69
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW, ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36(3):970-1062
   PubMed Web of Science ®Google Scholar
• George JC, Dangas GD. 2009 Focused updates to guidelines in ST-elevation myocardial infarction and percutaneous coronary intervention: application to interventional cardiology. JACC Cardiovasc Interv 2010;3(2):256-8
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116(7):e148-304
   PubMed Web of Science ®Google Scholar
• Tebaldi M, Arcozzi R, Campo G, The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2009;54(20):1900-1
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams RJ, Brown TM, Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010;121(7):e46-215
   PubMed Web of Science ®Google Scholar
• Hirsh J, Anand SS, Halperin JL, Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001;21(7):1094-6
   PubMed Web of Science ®Google Scholar
• Oler A, Whooley MA, Oler J, Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276(10):811-15
   PubMed Web of Science ®Google Scholar
• Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007;131(6):1644-9
   PubMed Web of Science ®Google Scholar
• Cohen M, Demers C, Gurfinkel EP, A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337(7):447-52
   PubMed Web of Science ®Google Scholar
• Antman EM, McCabe CH, Gurfinkel EP, Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100(15):1593-601
   PubMed Web of Science ®Google Scholar
• Ferguson JJ, Califf RM, Antman EM, Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292(1):45-54
   PubMed Web of Science ®Google Scholar
• Paolucci F, Clavies MC, Donat F, Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002;41(Suppl 2):11-18
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354(14):1464-76
   PubMed Web of Science ®Google Scholar
• Mehta SR, Granger CB, Eikelboom JW, Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007;50(18):1742-51
   PubMed Web of Science ®Google Scholar
• Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995;2(8):637-43
   PubMedGoogle Scholar
• Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921):81-106
   Google Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86
   PubMed Web of Science ®Google Scholar
• Balsano F, Rizzon P, Violi F, Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990;82(1):17-26
   PubMed Web of Science ®Google Scholar
• Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 1998;19(2):89-98
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363(10):930-42
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376(9749):1312-19
   PubMed Web of Science ®Google Scholar
• Price, M. The Gauging Responsiveness with A VerifyNow assay–Impact on Thrombosis And Safety (GRAVITAS). in AHA. 2010. Chicago
   Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001-15
   PubMed Web of Science ®Google Scholar
• Chattaraj SC. Cangrelor AstraZeneca. Curr Opin Investig Drugs 2001;2(2):250-5
   PubMedGoogle Scholar
• Bhatt, DL, Lincoff AM, Gibson CM, Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361(24):2330-41
   PubMed Web of Science ®Google Scholar
• Bouman HJ, van Werkum JW, Hackeng CM, Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. Neth Heart J 2009;17(5):195-8
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009;7(10):1195-201
   PubMedGoogle Scholar
• JJ Vang, Nilsson L, Berntsson P, Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7(9):1556-65
   PubMed Web of Science ®Google Scholar
• Weitz JI, Califf RM, Ginsberg JS, New antithrombotics. Chest 1995;108(Suppl 4):471S-85S
   PubMed Web of Science ®Google Scholar
• Ellis SG, Tendera M, de Belder MA, Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358(21):2205-17
   PubMed Web of Science ®Google Scholar
• ASSENT- 4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367(9510):569-78
   PubMed Web of Science ®Google Scholar
• Montalescot G, Borentain M, Payot L, Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004;292(3):362-6
   PubMed Web of Science ®Google Scholar
• Jeremias A, Vasu S, Gruberg L, Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Catheter Cardiovasc Interv 2010;75(6):895-902
   PubMed Web of Science ®Google Scholar
• The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339(7):436-43
   PubMed Web of Science ®Google Scholar
• Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357(9272):1915-24
   PubMed Web of Science ®Google Scholar
• ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345(8951):669-85
   PubMed Web of Science ®Google Scholar
• GISSI- 3 Investigators. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343(8906):1115-22
   PubMedGoogle Scholar
• Borrello F, Beahan M, Klein L, Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period. Rev Cardiovasc Med 2003;4(Suppl 3):S13-24
   PubMedGoogle Scholar
• Spargias KS, Hall AS, Greenwood DC, Beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart 1999;81(1):25-32
   PubMed Web of Science ®Google Scholar
• Otterstad JE, Ford I. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 2002;4(4):501-6
   PubMed Web of Science ®Google Scholar
• Hognestad A, Dickstein K, Myhre E, Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 2004;93(5):603-6
   PubMed Web of Science ®Google Scholar
• Kernis SJ, Harjai KJ, Stone GW, Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004;43(10):1773-9
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A, In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3(3):514-21
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics Xarelto. Available from: http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf
   Google Scholar
• Kubitza D, Becka M, Voith B, Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78(4):412-21
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46(5):549-58
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24(10):2757-65
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Wensing G, Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61(12):873-80
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban–an oral, direct factor Xa inhibitor–are not affected by aspirin. J Clin Pharmacol 2006;46(9):981-90
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29-38
   PubMed Web of Science ®Google Scholar
• Wallentin L, Wilcox RG, Weaver WD, Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362(9386):789-97
   PubMed Web of Science ®Google Scholar
• Oldgren J. Randomised dabigatran etexilate dose finding study In patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE-DEEM)" in AHA. Orlando; 2009
   Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358(26):2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372(9632):31-9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358(26):2776-86
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373(9676):1673-80
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510
   PubMed Web of Science ®Google Scholar
• Lopes RD, Starr A, Pieper CF, Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med 2010;123(2):134-40
   PubMed Web of Science ®Google Scholar
• Wang TY, Chen AY, Peterson ED, Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. Eur Heart J 2008;29(9):1103-9
   PubMed Web of Science ®Google Scholar
• Testa L, Zoccai GB, Porto I, Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 2007;99(12):1637-42
   PubMed Web of Science ®Google Scholar
• Konstantino Y, Iakobishvili Z, Porter A, Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 2006;105(2):80-5
   PubMed Web of Science ®Google Scholar